BSX Boston Scientific Corporation

Medical-device maker Boston Scientific Corp. said its loss narrowed in the fourth quarter as new product launches and a recent acquisition pushed sales higher.

For the Marlborough, Mass.-based company, stents and implantable heart-rhythm devices account for nearly half of the top line. Those product lines have been under increasing competitive pressure, and Boston Scientific has moved to diversify its product portfolio. Watchman, Boston Scientific's surgical device for preventing strokes, won U.S. regulatory approval last year, and during the quarter the company launched a new thrombectomy catheter to treat deep vein thrombosis.

Through its $1.6 billion acquisition last year of American Medical Systems' men's health and prostate businesses, Boston Scientific has also beefed up its MedSurg segment. Urology sales surged 77% from a year earlier to $256 million, thanks to the acquisition. That increase buoyed the overall MedSurg segment, which includes endoscopy and women's health devices.

Chief Executive Mike Mahoney said products and programs launched last year organically and through deals will support 2016 results. The company issued guidance Thursday that falls in line with analysts' projections.

In all for the fourth quarter, the company reported a loss of $142 million, or 11 cents a share, narrower than a year-earlier loss of $299 million, or 23 cents a share. Excluding acquisition and divestiture charges, among others, per-share profit rose to 26 cents from 22 cents.

Revenue increased 4.8% to $1.98 billion. Analysts projected 25 cents in adjusted earnings per share and $1.99 billion in sales, according to Thomson Reuters.

For the current year, Boston Scientific expects to report adjusted earnings of $1.03 to $1.07 a share, bracketing the $1.05 analysts have predicted. Sales, the company said, will grow 6% to 8% to $7.9 billion to $8.10 billion. Analysts have been looking for $8.05 in full-year revenue.

Shares in the company, down 5% over the past three months through Wednesday's close, were inactive premarket.

Write to Lisa Beilfuss at lisa.beilfuss@wsj.com

(END) Dow Jones Newswires

February 04, 2016 08:15 ET (13:15 GMT)

Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024